Abstract
Objectives. Pentraxin 3 (PTX3) is an acute phase marker, which is produced at the site of infection or inflammation in contrast to CRP that is mainly synthesized by the liver. The aim of the present study was to see if lifestyle interventions/weight loss would lead to decreased blood plasma concentrations of PTX3.Methods. Study subjects (n = 31) were recruited to a lifestyle intervention program aiming at increased physical activity, improved eating habits, and weight loss. High-sensitivity C-reactive protein (CRP) and PTX3 methods were used for analysis of CRP and PTX3 in plasma samples collected at inclusion and after 4 and 8 weeks of treatment.Results. Wilcoxon paired samples test showed a significant decrease in PTX3 concentrations from 2068 pg/mL at start to 2007 pg/mL at 4 weeks (P = 0.002) and 1748 pg/mL at 8 weeks (P = 0.003). The PTX3 decrease was not significantly correlated with a corresponding decrease in CRP or weight reduction.Conclusions. The lifestyle intervention program resulted in a significant reduction of circulating concentrations of pentraxin 3 already after 4 and 8 weeks of treatment.
Highlights
Pentraxin 3 (PTX3) is an acute phase protein consisting of 381 amino-acids and with a molecular weight of 42 kDa
Elevated plasma PTX3 concentrations were observed in patients with acute myocardial infarction (AMI) at admission [5]
Median blood plasma C-reactive protein (CRP) decreased from 1.32 mg/L at start to 1.21 mg/L (0.49–1.64; P = 0.27) after 4 weeks and 1.08 mg/L (0.62–1.59; P = 0.66) after 8 weeks
Summary
Pentraxin 3 (PTX3) is an acute phase protein consisting of 381 amino-acids and with a molecular weight of 42 kDa. Elevated plasma PTX3 concentrations were observed in patients with acute myocardial infarction (AMI) at admission [5]. The peak plasma PTX3 concentrations in this study were registered at 7.5 h after AMI. PTX3 concentrations turned out to be predictive of the occurrence of cardiovascular [8] and adverse events in patients with heart failure [9]. PTX3 is elevated in sleep apnea syndrome, while treatment reduced the plasma concentrations [10]. This association between PTX3 expression and CVD has been confirmed in animal models [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
